Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the Jones Las Vegas ...

Anixa Biosciences secured a USPTO patent allowance for its ovarian cancer vaccine, strengthening its IP position and ...

Anixa Biosciences, Inc. (NASDAQ:ANIX) entered into a letter of intent with VERDI Solutions GmbH to develop personalized and ...

Anixa Biosciences signed a letter of intent with VERDI Solutions to develop AI-powered personalized and off-the-shelf cancer ...

Anixa Biosciences (NASDAQ:ANIX – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC ...

Fintel reports that on March 21, 2025, Maxim Group initiated coverage of Anixa Biosciences (NasdaqCM:ANIX) with a Buy ...

Anixa Biosciences (ANIX) has entered into a letter of intent with Verdi Solutions to develop personalized and off-the-shelf peptide vaccines ...

Maxim Group assumed coverage on shares of Anixa Biosciences (NASDAQ:ANIX – Free Report) in a research note released on Friday ...

Anixa Biosciences (ANIX) announced that the United States Patent and Trademark Office, USPTO, has issued a Notice of Allowance for a key patent ...

SAN JOSE, Calif., March 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer ...

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine. Anixa Biosciences, Inc. March 24, 2025.

Anixa Biosciences gets notice of allowance for patent application for its ovarian cancer vaccine technology from USPTO: San Jose, California Thursday, March 27, 2025, 17:00 Hrs [I ...